Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors. | EJNMMI Res;1(1): 20, 2011 Sep 01. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors.

Rousseau, Caroline; Ruellan, Anne Lise; Bernardeau, Karine; Kraeber-Bodéré, Françoise; Gouard, Sebastien; Loussouarn, Delphine; Saï-Maurel, Catherine; Faivre-Chauvet, Alain; Wijdenes, John; Barbet, Jacques; Gaschet, Joëlle; Chérel, Michel; Davodeau, François.

Affiliation

Rousseau C; Centre de Recherche en Cancérologie de Nantes-Angers, Université de Nantes, Inserm, U892, Nantes, France. davodeau@nantes.inserm.fr.

EJNMMI Res ; 1(1): 20, 2011 Sep 01.

Article in En | MEDLINE | ID: mdl-22214534

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: EJNMMI Res Year: 2011 Document type: Article Affiliation country: France Country of publication: Germany

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: EJNMMI Res Year: 2011 Document type: Article Affiliation country: France Country of publication: Germany